Non-Dilutive Funding:Finding It, Getting It, and Using It Strategically to Move Your Company Forward

Wednesday, March 06, 2013 (7:30 AM - 12:00 PM)

Topic Description:  
It’s no secret that funding a life science business is harder than ever.  The contraction of venture capital and cuts to federal grant budgets have made securing non-dilutive funding more difficult, yet ever more crucial to validating technology  and reducing risk early on.  Don’t miss this event if you want learn more about the varied sources of non-dilute capital available to life science companies in Washington and how best to go about finding it, getting it, and using it smartly.

 This is Part I of a 2-part series. Part II, focused on venture capital, will be held at LSINW July 10-11, 2013.

 Learning Objectives:

  • How do you find out about non-dilute funding sources and what they fund?
  • What do funders look for in funding proposals?
  • How do you create, establish and maintain a grant budget?
  • How do you align project flow with additional grants and follow-on funding?
  • When can you use grants strategically to fund specific milestones?
  • What service providers do you need to assist with obtaining and managing non-dilute capital?

Who Should Attend:

  • Early stage company leaders
  • Researchers, students and post-docs working on commercializable ideas and products
  • Grant writers and project managers
  • Service providers who support and manage grant-funded projects

Our Expert Panelists:

  • Susan Ashe, Executive Director, Health Sciences & Services Authority, Spokane WA
  • Patricia Beckman, PhD, Founder, BioStrategy, LLC
  • Christiana DelloRusso, PhD, Director, Commercialization, Washington Biotechnology & Biomedical Association 
  • John DesRosier, PhD, Executive Director, Life Sciences Discovery Fund
  • Jeanette Ennis, Grant Funding Manager, University of Washington Center for Commercialization
  • Anson Fatland, Associate Vice President for Economic Development and External Affairs, Washington State University
  • Stephanie Fertig, Project Manager, Small Business Program, NINDS, National Institutes of Health
  • Allison Formal, Vice President Research & Business Development, The Leukemia  & Lymphoma Society
  • Michael Hite, President and Chief Executive Officer, Impel Neuropharma
  • Jim Katzaroff, Founder, Chairman & Chief Executive Officer, Advanced Medical Isotope Corporation
  • Erik Nilsson, Chief Executive Officer, Insilicos
  • Bart Phillips, Vice President, Economic Development, Innovate Washington
  • Matthew Scholz, Chief Executive Officer, Immusoft Corporation
  • Gary Spanner, Director, Economic Development Office, Pacific Northwest National Laboratory
  • Rick Shindell, SBIR Gateway


7:30 AM - Noon
Registration - 7:30 AM
Program  - 8:00 - Noon

Registration Fees:
WBBA Member- $40.00                     
Future Member- $80.00                     
Academia, Nonprofit, Student- $35.00 

Thank you to our sponsors:


© 2012 Washington Biotechnology & Biomedical Association

Powered by